ExxonMobil's Bold Bet on the Permian Basin: Massive Growth Ahead?
XOM is using innovative technologies to achieve this. To keep underground cracks open, which continuously allow more oil and natural gas to flow out of wells, the large integrated energy company has been employing a special material called lightweight proppant. Thus, XOM has been successful in boosting recovery rates to 20% from 15% just a few months ago. This is how the energy giant has become successful in pulling out more oil from the same wells.
The integrated energy player is thus showcasing a solid production outlook for the years to come. In the most prolific basin, ExxonMobil projects a ramping up of production to 2.3 MMBoE/D by 2030, suggesting a jump from the current 1.6 MMBoE/D.
CVX & FANG's Solid Permian Footprint
Like XOM, Chevron CVX and Diamondback Energy, Inc. FANG also produce significant volumes of oil and natural gas from the Permian.
Chevron has a strong footprint in the Permian. With more than 2 million net acres of land, CVX has been operating in the basin for more than 100 years.
Diamondback Energy is a pure-play Permian operator. FANG has a huge inventory of oil and gas wells, thereby showcasing a solid production outlook.
XOM's Price Performance, Valuation & Estimates
Shares of XOM have declined 4.7% over the past year against the 4% rise of the industry.
From a valuation standpoint, XOM trades at a trailing 12-month enterprise value to EBITDA (EV/EBITDA) of 6.93X. This is above the broader industry average of 4.31X.
The Zacks Consensus Estimate for XOM's 2025 earnings has been revised upward over the past seven days.
ExxonMobil currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.
See "2nd Wave" AI stocks now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Chevron Corporation (CVX): Free Stock Analysis Report
Exxon Mobil Corporation (XOM): Free Stock Analysis Report
Diamondback Energy, Inc. (FANG): Free Stock Analysis Report
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
22 minutes ago
- CTV News
Carney is ‘bending over backwards' for Trump: Poilievre on Canada-U.S. trade deal
Conservative Leader Pierre Poilievre claims Mark Carney has 'made concession after concession' to Donald Trump when it comes to a trade deal with the U.S.
National Post
22 minutes ago
- National Post
Toronto FC adds to its attack, acquiring Djordje Mihailovic as a designated player
Toronto FC has acquired Djordje Mihailovic from the Colorado Rapids in a cash deal worth up to $9 million (all figures in U.S. dollars), hoping the attacking midfielder will help revive its attack. Article content The transfer cost Toronto $8 million with up to $1 million in conditional cash if certain performance-based metrics are met. Colorado also retains a sell-on percentage if the player is traded or transferred. Article content Article content Mihailovic joins Toronto as a designated player, signing a 3 1/2-year contract through the end of 2028 with a club option for 2029. Article content 'The signing of Djordje is a landmark moment, not just for our team, but for our fans, as the clearest symbol of our ownership's intention and commitment to winning,' Toronto general manager Jason Hernandez said in a statement. 'As we determined the best strategy to approach our team's transformation, we identified Djordje as the perfect foundational piece for our club, as one of the most prolific chance-creators in MLS. Article content 'Djordje's ability to deliver high-level output week in and week out is widely understood, but his winning mentality and desire to elevate TFC were key factors in securing him as our new No. 10 … We know Djordje is only beginning to enter his prime and will be a key piece of our franchise for many years to come.' Article content Earlier Thursday, TFC announced it had acquired $175,000 in 2025 general allocation money from the Portland Timbers in exchange for a 2025 international roster slot. Article content The Mihailovic transfer is the latest in a line of big moves in Major League Soccer this week with German star Thomas Muller joining the Vancouver Whitecaps from Bayern Munich and South Korean captain Son Heung-Min joining Los Angeles FC from England's Tottenham. Article content At his best, Mihailovic is a game-changer, something Toronto (5-13-6) sorely needs. With 25 goals in 24 games, TFC ranks 26th in the league on offence. Article content Mihailovic can score goals and set them up. The 26-year-old U.S. international has scored 48 goals and added 63 assists in 243 games during a pro career in MLS and Europe. Article content The five-foot-10 153-pounder has 23 goals and 22 assists in 63 appearances in all competitions with Colorado since joining the club as a DP in January 2024. In his first season with the Rapids, he set a club record for most goal contributions in a single season with 11 goals and 14 assists in regular-season play.
Globe and Mail
22 minutes ago
- Globe and Mail
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion's 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient's vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant. Esperion Therapeutics Esperion Therapeutics, Inc. is a commercial stage biopharmaceutical company focused on bringing new medicines to market that address unmet needs of patients and healthcare professionals. The Company developed and is commercializing the only U.S. Food and Drug Administration (FDA) approved oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease and are struggling with elevated low density lipoprotein cholesterol (LDL-C). These medications are supported by the nearly 14,000 patient CLEAR Cardiovascular Outcomes Trial. Esperion continues to build on its success with its next generation program which is focused on developing ATP citrate lyase inhibitors (ACLYi). New insights into the structure and function of ACLYi fully enables rational drug design and the opportunity to develop highly potent and specific inhibitors with allosteric mechanisms. Esperion continues to evolve into a leading global biopharmaceutical company through commercial execution, international partnerships and collaborations and advancement of its pre-clinical pipeline. For more information, visit and follow Esperion on LinkedIn and X.
